Want to see IN:INNOVACAP full AI Analyst Report?
INNOVACAP Stock Chart & Stats
₹957.45
₹7.35(0.77%)
At close: 4:00 PM EDT
₹957.45
₹7.35(0.77%)
Day’s Range― - ―
52-Week Range₹608.25 - ₹1,350.05
Previous CloseN/A
Volume8.81K
Average Volume (3M)69.27K
Market Cap
₹57.36B
Enterprise Value₹42.05B
Total Cash (Recent Filing)₹682.50M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)36.4
Beta0.77
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)26.91
Shares Outstanding57,224,930
10 Day Avg. Volume5,466
30 Day Avg. Volume69,270
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)3.62
Price to Sales (P/S)2.46
P/FCF Ratio114.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33.05
Revenue Forecast (FY)₹20.19B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthStrong revenue expansion indicates growing demand for Innova Captab’s finished formulations and manufacturing services. If maintained, this scale can broaden customer relationships, improve operating leverage, and support continued investment in pharmaceutical production and development capabilities over the next several quarters.
Solid ProfitabilityHealthy operating and net margins, together with rising net income, show that growth is translating into earnings rather than being purely volume-led. This profitability provides an internal funding base for capacity, product development, and customer servicing while supporting resilience through normal industry fluctuations.
Improving Leverage And Healthy ReturnsImproving debt-to-equity strengthens financial flexibility and reduces the balance-sheet burden associated with expansion. Consistently healthy returns on equity indicate that the enlarged capital base is still generating attractive earnings, although the normalization from earlier peaks warrants ongoing monitoring.
Bears Say
Historically Negative Free Cash FlowRepeatedly negative free cash flow means reported earnings have not consistently converted into surplus cash. This can constrain self-funded expansion, increase reliance on external financing or working-capital management, and leave less financial flexibility if investment needs remain elevated over the coming quarters.
Weak Cash-flow ConversionOperating cash flow that trails reported earnings reduces earnings quality and limits the cash available for reinvestment, debt reduction, or other capital allocation. Until conversion improves, strong accounting profitability may provide less practical support for sustained growth than headline results suggest.
Gross-margin VolatilityThe decline in gross margin introduces uncertainty around the durability of current profitability. If mix, pricing, or cost pressures persist, further revenue growth may deliver less incremental earnings and could weaken the company’s ability to absorb investment and operating costs across its formulation portfolio.
Innova Captab Limited News
INNOVACAP FAQ
What was Innova Captab Limited’s price range in the past 12 months?
Innova Captab Limited lowest stock price was ₹608.25 and its highest was ₹1350.05 in the past 12 months.
What is Innova Captab Limited’s market cap?
Innova Captab Limited’s market cap is ₹57.36B.
When is Innova Captab Limited’s upcoming earnings report date?
Innova Captab Limited’s upcoming earnings report date is Nov 06, 2026 which is in 13 days.
How were Innova Captab Limited’s earnings last quarter?
Innova Captab Limited released its earnings results on Aug 11, 2026. The company reported ₹7.7 earnings per share for the quarter, beating the consensus estimate of ₹3.4 by ₹4.3.
Is Innova Captab Limited overvalued?
According to Wall Street analysts Innova Captab Limited’s price is currently Overvalued.
Does Innova Captab Limited pay dividends?
Innova Captab Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.2%. See more information on Innova Captab Limited dividends here
What is Innova Captab Limited’s EPS estimate?
Innova Captab Limited’s EPS estimate is 8.
How many shares outstanding does Innova Captab Limited have?
Innova Captab Limited has 57,224,930 shares outstanding.
What happened to Innova Captab Limited’s price movement after its last earnings report?
Innova Captab Limited reported an EPS of ₹7.7 in its last earnings report, beating expectations of ₹3.4. Following the earnings report the stock price went up 5.494%.
Which hedge fund is a major shareholder of Innova Captab Limited?
Currently, no hedge funds are holding shares in IN:INNOVACAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Innova Captab Limited
Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution and marketing, serving both domestic and international markets. The company also extends Contract Development and Manufacturing Organization (CDMO) services to other pharmaceutical businesses within India. Furthermore, Innova Captab is actively involved in developing, producing, and supplying a diverse array of generic medications. These formulations address a broad range of therapeutic areas, including anti-infectives (such as cephalosporins and antivirals), gastrointestinal treatments (like proton pump inhibitors and antiemetics), pain and inflammation management (including NSAIDs and analgesics), respiratory and allergy relief, cardiovascular support, antidiabetics, various neurological and psychiatric therapies, and solutions for urological conditions, among numerous other specialized segments. These pharmaceutical offerings are provided in multiple forms, such as tablets, capsules, dry syrups, injectable powders, ointments, and liquid oral preparations. Innova Captab distributes its branded generic products through an extensive network of distributors and pharmacies, in addition to utilizing various online e-commerce pharmacy platforms.
Technical Analysis
Bliss Gvs Pharma Limited
―
Gufic Biosciences Limited
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―